486 related articles for article (PubMed ID: 21368455)
21. NAD(+) consumption in carcinogen-treated hamster cells overexpressing a dominant negative mutant of poly(ADP-ribose) polymerase.
Küpper JH; Müller M; Wolf I
Biochem Biophys Res Commun; 1999 Nov; 265(2):525-9. PubMed ID: 10558902
[TBL] [Abstract][Full Text] [Related]
22. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.
Lewis C; Low JA
Curr Opin Investig Drugs; 2007 Dec; 8(12):1051-6. PubMed ID: 18058575
[TBL] [Abstract][Full Text] [Related]
23. [Clinical development of PARP inhibitors].
Toyoda M; Minami H
Gan To Kagaku Ryoho; 2012 Apr; 39(4):519-24. PubMed ID: 22504675
[TBL] [Abstract][Full Text] [Related]
24. BRCA in breast cancer: from risk assessment to therapeutic prediction.
Diamond JR; Borges VF; Eckhardt SG; Jimeno A
Drug News Perspect; 2009 Dec; 22(10):603-8. PubMed ID: 20140280
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
Drew Y; Mulligan EA; Vong WT; Thomas HD; Kahn S; Kyle S; Mukhopadhyay A; Los G; Hostomsky Z; Plummer ER; Edmondson RJ; Curtin NJ
J Natl Cancer Inst; 2011 Feb; 103(4):334-46. PubMed ID: 21183737
[TBL] [Abstract][Full Text] [Related]
26. Small-molecule PARP modulators--current status and future therapeutic potential.
Penning TD
Curr Opin Drug Discov Devel; 2010 Sep; 13(5):577-86. PubMed ID: 20812149
[TBL] [Abstract][Full Text] [Related]
27. Poly ADP-ribose polymerase-1 and health.
Kirkland JB
Exp Biol Med (Maywood); 2010 May; 235(5):561-8. PubMed ID: 20463295
[TBL] [Abstract][Full Text] [Related]
28. Development of PARP inhibitors in oncology.
Rodon J; Iniesta MD; Papadopoulos K
Expert Opin Investig Drugs; 2009 Jan; 18(1):31-43. PubMed ID: 19053880
[TBL] [Abstract][Full Text] [Related]
29. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.
Ratnam K; Low JA
Clin Cancer Res; 2007 Mar; 13(5):1383-8. PubMed ID: 17332279
[TBL] [Abstract][Full Text] [Related]
30. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
[TBL] [Abstract][Full Text] [Related]
31. The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment.
Sandhu SK; Yap TA; de Bono JS
Curr Drug Targets; 2011 Dec; 12(14):2034-44. PubMed ID: 21777194
[TBL] [Abstract][Full Text] [Related]
32. [Neuronal death: potential role of the nuclear enzyme, poly (ADP-ribose) polymerase].
Boulu RG; Mesenge C; Charriaut-Marlangue C; Verrecchia C; Plotkine M
Bull Acad Natl Med; 2001; 185(3):555-63; discussion 564-5. PubMed ID: 11501263
[TBL] [Abstract][Full Text] [Related]
33. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
[TBL] [Abstract][Full Text] [Related]
34. [Poly(ADP-ribose) polymerase-1 as a regulator of protein-nucleic acid interactions in the processes responding to genotoxic action].
Sukhanova MV; Lavrik OI; Khodyreva SN
Mol Biol (Mosk); 2004; 38(5):834-47. PubMed ID: 15554186
[TBL] [Abstract][Full Text] [Related]
35. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors.
Jagtap P; Szabó C
Nat Rev Drug Discov; 2005 May; 4(5):421-40. PubMed ID: 15864271
[TBL] [Abstract][Full Text] [Related]
36. PARP inhibitors in cancer therapy: an update.
Papeo G; Casale E; Montagnoli A; Cirla A
Expert Opin Ther Pat; 2013 Apr; 23(4):503-14. PubMed ID: 23379721
[TBL] [Abstract][Full Text] [Related]
37. Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.
Kyle S; Thomas HD; Mitchell J; Curtin NJ
Br J Radiol; 2008 Oct; 81 Spec No 1():S6-11. PubMed ID: 18820000
[TBL] [Abstract][Full Text] [Related]
38. [PARP inhibitors--theoretical basis and clinical application].
Dębska S; Kubicka J; Czyżykowski R; Habib M; Potemski P
Postepy Hig Med Dosw (Online); 2012 May; 66():311-21. PubMed ID: 22706117
[TBL] [Abstract][Full Text] [Related]
39. PARP inhibitors for cancer therapy.
Curtin NJ
Expert Rev Mol Med; 2005 Mar; 7(4):1-20. PubMed ID: 15836799
[TBL] [Abstract][Full Text] [Related]
40. PARP inhibitors in breast cancer.
Telli ML; Ford JM
Clin Adv Hematol Oncol; 2010 Sep; 8(9):629-35. PubMed ID: 21157412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
